Patent 7902401 was granted and assigned to Nps Pharmaceuticals on March, 2011 by the United States Patent and Trademark Office.
Compounds of Formula I are useful in the treatment of epilepsy, neuropathic pain, acute and chronic inflammatory pain, migraine, tardive dyskinesia and other related CNS disorders.